This is one of the largest sources of frustration currently among health care companies and investors.
Global Cancer Consortium
This Week in Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
January/February 2012
The OneMedResearch January/February 2012 Issue discusses the developments of several small companies with intriguing technology in an emerging market. The report contains full financial updates of those companies designated as research clients as […]
BREAKING NEWS: Advaxis Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies.
Provectus Receives Guidance From FDA On Pathway to Approval for Phase 3 Trial of PV-10 For Metastatic Melanoma
Dr. Craig Dees talks candidly in a live audio interview about the company’s developments.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Biocept, Inc. Making Advances in Circulating Tumor Cell Research for Cancers
To date, most CTC capture and detection technologies have not been able to recognize the cytokeratin negative (CK‐) CTCs. Biocept’s Cell Enrichment and Extraction (CEETM) platform allows for the capture of these CK- cells as well as CK+ CTC phenotypes
